Comparison
Cagrilintide vs. Semaglutid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
1415456-99-3
910463-68-2
Molecular weight
4253.7 g/mol
4113.6 g/mol
Half-life
168 h
165 h
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYmodifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerMechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
4
of which in humans
3
3
Effects recorded
3
3
Open conflicts
0
1
Documented adverse events
1
5